Vaxcyte PCVX Cash Flow Statement (2019-2026)

NASDAQ PCVX
$68.62 +2.26 (+3.41%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Vaxcyte Quarterly Cash Flow Statement

Periods 31 quarters
Latest Sep 2026

Vaxcyte reported cash from operations of -$224.08M and free cash flow of -$227.42M for the quarter ended Sep 2026, down 56.4% year over year. This cash flow statement covers 31 quarters of results from Mar 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-28.56M-38.99M-48.53M-57.92M-78.05M-60.46M-68.34M-92.66M-180.80M-95.02M-128.70M-103.12M-137.08M-140.72M-166.57M-212.83M-246.51M-320.62M-284.30M-297.06M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
4.11M
Depreciation & Amortization (CF)Dep. & Amort.
0.46M0.58M0.61M0.68M0.96M0.71M0.75M0.81M0.89M1.00M1.35M1.79M2.86M2.96M2.88M3.06M7.50M2.95M3.00M5.78M
Share-based CompensationStock Comp.
3.16M4.10M5.89M6.65M7.01M9.65M12.54M13.22M13.35M17.63M21.56M21.27M24.37M30.62M36.93M35.31M36.00M37.96M41.24M41.10M
Gains from Sales and DivestituresGains Divest
-0.07M-0.04M
Asset Writedowns and ImpairmentWritedown
0.06M0.16M
Other non-cash itemsOther Non-Cash
0.75M1.79M1.56M1.67M1.60M1.63M1.65M1.67M2.06M2.09M2.13M-3.75M12.61M-4.70M-23.60M1.34M0.65M5.11M8.10M13.90M
Change in Working Capital
Change in Account PayablesChange Payables
-18.07M-1.93M2.71M-1.35M3.47M1.79M2.26M0.69M6.48M5.67M-10.71M8.31M31.31M-29.16M9.53M17.88M21.67M-0.27M31.55M-32.86M
Change in Accrued ExpensesChange Accrued Exp.
-3.82M-2.19M3.74M3.92M1.69M3.04M0.20M2.51M30.55M-7.97M-27.00M8.64M-9.32M-14.42M4.55M5.95M9.89M-15.57M6.20M7.14M
Change in Other Operating AssetsOther Assets Change
-8.43M-1.21M1.53M-2.63M2.35M4.09M-0.47M-7.41M35.66M13.54M3.55M12.12M53.08M25.63M17.14M10.40M55.88M25.62M39.28M11.19M
Change in Other Operating LiabilitiesOther Liabilities Change
10.19M-3.20M-0.82M6.86M2.14M8.05M0.79M28.91M18.04M-1.80M-1.84M2.38M20.21M16.00M-1.36M-1.40M64.20M-1.29M-0.85M-1.39M
Other Working Capital ChangesOther WC Changes
18.62M-1.99M-2.35M9.50M-0.21M3.96M1.26M36.32M-17.62M-15.34M-5.39M-9.74M-32.87M-9.63M-18.51M-11.80M8.31M-26.90M-40.13M-12.58M
Cash from OperationsCash from Ops.
-51.09M-27.70M-39.13M-38.55M-65.22M-47.69M-62.74M-57.55M-128.81M-159.12M-121.39M-60.71M-111.40M-166.27M-121.17M-143.31M-224.83M-280.63M-232.47M-224.08M
Investing Activities
Capital ExpendituresCapex
1.38M2.92M0.94M0.84M1.14M5.61M-2.14M7.34M5.25M5.68M7.78M4.95M4.02M5.42M1.81M3.82M2.65M2.11M4.32M3.34M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.03M0.01M
Change in Property, Plant and EquipmentChange in PP&E
-1.36M-2.91M-0.94M-0.84M-1.14M-5.61M2.14M-7.34M-5.25M-5.68M-7.78M-4.95M-4.02M-5.42M-1.81M-3.82M-2.65M-2.11M-4.32M-3.34M
Purchase of InvestmentsInvestments Purchased
41.06M6.97M6.90M17.59M71.29M483.78M432.83M209.67M203.61M687.70M350.65M1,233.14M815.22M314.49M349.05M255.32M292.65M584.13M268.68M236.32M
Sale and Maturity of InvestmentsInvestments Sold
42.50M59.55M34.00M53.14M36.48M41.29M97.13M239.29M246.75M248.70M309.22M354.20M288.07M464.55M436.55M388.53M416.20M365.51M420.97M412.05M
Other Investing Activities (as filed)Other investing (as filed)
1.10M0.22M0.00M1.32M0.15M0.00M1.47M0.00M-0.21M
Cash from Investing ActivitiesCash from Investing
0.08M49.67M26.17M34.71M-35.95M-448.10M-333.56M22.28M-13.93M-451.07M-80.41M-917.02M-557.17M123.32M77.74M121.17M115.13M-233.41M147.72M170.77M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment
Net Long-Term Debt Issued (Repaid)Net LT Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
8.75M3.40M49.88M44.88M5.08M42.29M1.90M51.16M3.04M5.02M110.91M101.20M5.96M6.05M3.24M0.31M3.42M9.03M7.76M7.32M
Shares Repurchased
Net Shares Issued and RepurchasedNet Shares Issued
8.75M3.40M49.88M44.88M5.08M42.29M1.90M51.16M3.04M5.02M110.91M101.20M5.96M6.05M3.24M0.31M3.42M9.03M7.76M7.32M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
8.75M3.40M49.88M44.88M5.08M42.29M1.90M51.16M3.04M5.02M110.91M101.20M5.96M6.05M3.24M0.31M3.42M9.03M7.76M7.32M
Other financing activities (as filed)
-0.86M-0.73M-0.21M-2.61M-0.33M-3.31M-0.57M-9.34M-1.09M-5.29M-0.72M-3.98M-1.01M-9.30M-2.06M-12.64M
Cash from Financing ActivitiesCash from Financing
8.75M111.02M49.88M44.02M656.63M41.56M546.97M48.55M2.74M818.20M110.37M1,515.04M4.91M0.76M2.52M-3.67M2.41M601.58M5.70M-5.33M
Additional items
Exchange Rate EffectFX Effect
-0.80M-0.23M-0.49M0.05M0.80M0.02M-0.08M1.05M-7.68M6.06M-1.41M-5.58M1.35M1.17M0.80M0.29M0.18M-0.66M1.40M0.70M
Change in Cash
-43.06M132.76M36.43M40.23M556.26M-454.21M150.58M14.33M-147.68M214.06M-92.84M531.73M-662.31M-41.03M-40.11M-25.52M-107.12M86.88M-77.65M-57.93M
Ending Cash Balance
69.86M202.61M239.04M279.27M835.53M381.32M531.90M546.24M398.55M612.62M519.77M1,051.51M389.20M348.17M308.06M282.55M175.43M262.31M184.66M126.72M
Free Cash FlowFCF
-52.48M-30.62M-40.06M-39.39M-66.36M-53.30M-60.60M-64.89M-134.06M-164.80M-129.18M-65.66M-115.42M-171.70M-122.98M-147.13M-227.49M-282.73M-236.79M-227.42M
Net Cash FlowNCF
-42.26M132.98M36.92M40.18M555.46M-454.23M150.66M13.28M-140.00M208.00M-91.43M537.31M-663.66M-42.20M-40.91M-25.81M-107.30M87.55M-79.05M-58.64M
Interest Paid

Vaxcyte Cash Flow Statement API

Pull Vaxcyte's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=PCVX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY